Genentech Seeking to Expand Tarceva into First-Line Setting in EGFR-Mutated NSCLC Patients
June 08, 2011
Genentech Seeking to Expand Tarceva into First-Line Setting in EGFR-Mutated NSCLC Patients
Data presented at ASCO this week showed that NSCLC patients with EGFR mutations who received Tarceva lived twice as long without their disease progressing compared to patients who received platinum-based chemotherapy, which is currently the standard of care for first-line NSCLC therapy.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter - Roche Gets EC Nod for Tarceva as First-Line Therapy in EGFR-mutated NSCLC; Awaits CE Mark for CDx
September 7, 2011 / Pharmacogenomics Reporter - Roche Receives FDA Nod for New PGx Indication for Tarceva in Metastatic NSCLC with Companion Dx
May 15, 2013 / Pharmacogenomics Reporter - Pharmas and Dx Partners Race to Launch the First Personalized EGFR Inhibitor for Lung Cancer
January 16, 2013 / Pharmacogenomics Reporter - During Investor Day, Roche Highlights Personalized Medicine as Key Area for Future Growth
September 12, 2012 / Pharmacogenomics Reporter